-
Information-Publications
-
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cellsDetails
-
Circular RNA CircSLC22A23 Promotes Gastric Cancer Progression by Activating HNRNPU ExpressionDetails
-
THUMPD2 catalyzes the N2-methylation of U6 snRNA of the spliceosome catalytic center and regulates pre-mRNA splicing and retinal degenerationDetails
-
GABA/Baclofen Enhances Immunotherapy of Breast Cancer by Stabilizing PD-L1Details
-
Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In VivoDetails
-
Kdm4a is an activity downregulated barrier to generate new engram for memory separationDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands